Business News • PR NewsWire • Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio

NEW YORK, July 25, 2022 /PRNewswire/ -- DLBCL is a cancer of B-lymphocytes and is the most common type of Non-Hodgkins Lymphoma (NHL) among adults. It is a fast-growing and complex form of NHL and is difficult to treat. NHL refers to a group of cancers of the lymphatic system that...

View More : https://www.prnewswire.com:443/news-releases/diffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-size-to-grow-by-usd...

Releted News by prnewswire

AI-Based Medical Imaging Market to Reach $11,921.4 Million by 2030, says P&S Intelligence

Ozonetel Commended by Frost & Sullivan for Its Highly Differentiated Cloud-based Contact Center Solutions with Trendsetting, Cost-effective Features

Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1

Global Professional Headset Market Boosted by the Popularity of Hybrid Work Model

Western Global Airlines Selects ACL Airshop as a Strategic Partner for Air Cargo Equipment & Logistics Support